Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001140361-23-054445
Filing Date
2023-11-22
Accepted
2023-11-22 16:15:20
Documents
1
Group Members
DAVID C. OTTO. ANDREAS HALVORSENROSE S. SHABETVIKING GLOBAL EQUITIES MASTER LTD.VIKING GLOBAL OPPORTUNITIES GP LLCVIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTERVIKING GLOBAL OPPORTUNITIES PARENT GP LLCVIKING GLOBAL OPPORTUNITIES PORTFOLIO GP

Document Format Files

Seq Description Document Type Size
1 SC 13D/A ef20015099_sc13da.htm SC 13D/A 360511
  Complete submission text file 0001140361-23-054445.txt   362650
Mailing Address 600 WASHINGTON BLVD. FLOOR 11 STAMFORD CT 06901
Business Address 600 WASHINGTON BLVD. FLOOR 11 STAMFORD CT 06901 212-672-7050
VIKING GLOBAL INVESTORS LP (Filed by) CIK: 0001103804 (see all company filings)

EIN.: 134055118 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304
Business Address 3160 PORTER DR. SUITE 250 PALO ALTO CA 94304 (650) 391-9740
BridgeBio Pharma, Inc. (Subject) CIK: 0001743881 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-91059 | Film No.: 231433664
SIC: 2834 Pharmaceutical Preparations